Search

Your search keyword '"Santarpia, L."' showing total 68 results
Start Over Author "Santarpia, L." Database OpenAIRE
68 results on '"Santarpia, L."'

3. Identification of microRNAs targeting the DNA damage response in breast cancer

Author

BISSO, ANDREA, FALESCHINI, MICHELA, ZAMPA, FEDERICO, DEL SAL, GIANNINO, Piazza, S., Santarpia, L., Cappelletti, V., Daidone, M. G., Agami, R., ABCD, Bisso, Andrea, Faleschini, Michela, F., Zampa, S., Piazza, L., Santarpia, V., Cappelletti, M. G., Daidone, R., Agami, G., Del Sal, ABCD e SIBBM, Zampa, Federico, Piazza, S., Santarpia, L., Cappelletti, V., Daidone, M. G., Agami, R., and DEL SAL, Giannino

Subjects
breast cancer, atm, microRNA, miR-181, microRNA, miR-181, ATM
Abstract

Several in vivoand in vitro data demonstrated that the DNA damage response (DDR) plays a crucial role in tumorigenesisacting as an anti-cancer barrier. Indeed, cells respond to DNA breaks caused by both exogenous (e.g. chemicals, chemotherapeutics) and endogenous (e.g. deregulated function of oncogenes) sources of DNA damages by properly triggering the activation of the DDR. The latter involves the recruitment of DNA repair proteins to sites of damage and the activation of checkpoint mechanisms to slow down cell cycle progression, thus allowing DNA damage repair or, if the damage could not be repaired, leading to apoptosis or cellular senescence. As a consequence, alterations of DDR functionality have a deep impact on cell proliferation, survival, genomic instability and tumorprogression. microRNAs(miRNAs) are small non coding RNAs that finely regulate gene expression by binding the 3’UTR of their target mRNAs, thus altering theirtranslation, stability and localization. It has been shown that several miRNAsmodulate critical cellular processes deregulated in cancer, acting either as oncogenesor tumorsuppressors. In the present study, we focused on the identification of miRNAsas new modulators of DNA damage activated signalingin several normal and transformed breast cancer cells. In particular, we discovered that miR-181 family acts as a modulator of the levels of ATM (ataxia telangiectasiamutated) kinase, one of the most important proteins involved in sensing DNA double strand breaks and activating DDR. The role of miR-181 family in the DDR pathway, its involvement in the induction of cellular senescence triggered by oncogenicstress (OIS) and its relevance in breast cancer will be presented.

Published
2011

5. Treatment of HBeAg negative chronic hepatitis B with the 'de novo' combination lamivudine and adefovir (THECLA): interim analysis of a prospective, multi center study

Author

7. Ruggiero G, ZAMPINO, Rosa, Rainone I, DURANTE MANGONI, Emanuele, Guerrera B, Andreana L, Boemio A, Cesaro G, Santarpia L, Attanasio V, Coppola C, Natale G, Niro G, Tallarico F, Oliviero P, Cafaro M., MARRONE, Aldo, 7., Ruggiero G, Marrone, Aldo, Zampino, Rosa, Rainone, I, DURANTE MANGONI, Emanuele, Guerrera, B, Andreana, L, Boemio, A, Cesaro, G, Santarpia, L, Attanasio, V, Coppola, C, Natale, G, Niro, G, Tallarico, F, Oliviero, P, and Cafaro, M.

Published
2008

6. La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico

Author

Florio A, Restivo L, ZAMPINO, Rosa, Andreana A, Cesaro G, Santarpia L, De Rosa C, Rinaldi L, Tripodi MF, MARRONE, Aldo, ADINOLFI, Luigi Elio, Ruggiero G., Florio, A, Restivo, L, Zampino, Rosa, Andreana, A, Cesaro, G, Santarpia, L, De Rosa, C, Rinaldi, L, Tripodi, Mf, Marrone, Aldo, Adinolfi, Luigi Elio, and Ruggiero, G.

Published
2007

12. Effects of long-term alfa interferon treatment in 344 patients with chronic hepatitis C: retrospective analysis of dosage and type of interferon used

Author

ANDREANA A, UTILI, Riccardo, ADINOLFI, Luigi Elio, CESARO G, SANTARPIA L, TRIPODI MF, ROSARIO P, ZAMPINO, Rosa, MORMONE G, RAGONE E, MARRONE, Aldo, TONZIELLO A, BELLOPEDE P, RUGGIERO G., Andreana, A, Utili, Riccardo, Adinolfi, Luigi Elio, Cesaro, G, Santarpia, L, Tripodi, Mf, Rosario, P, Zampino, Rosa, Mormone, G, Ragone, E, Marrone, Aldo, Tonziello, A, Bellopede, P, and Ruggiero, G.

Published
1997

13. A novel point mutation in the ligand-binding domain of the human glucocorticoid receptor (hGR) in a patient with glucocorticoid resistance

Author

Salvatore Cannavo, Karl, M., Santarpia, L., Facchiano, A., Marabotti, A., Trimarchi, F., and Benvenga, S.

Subjects
Glucocorticoid, menstrual abnormalities, glucocorticoid hormone resistance, Glucocorticoid, glucocorticoid receptor mutations, glucocorticoid hormone resistance, hirsutism, menstrual abnormalities, glucocorticoid receptor mutations, hirsutism
Published
2007

25. Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study

Author

UTILI, Riccardo, Sagnelli E, GAETA, Giovanni Battista, Galanti B, Nardiello S, Felaco MF, Pasquale G, MARRONE, Aldo, Aprea L, Pizzella T, Digilio L, Cesaro G, Sardaro C, Santarpia L, ADINOLFI, Luigi Elio, Andreana A, Russo M, FILIPPINI, Pietro, ZAMPINO, Rosa, Piccinino F, Ruggiero G, Giusti G., Utili, Riccardo, Sagnelli, E, Gaeta, Giovanni Battista, Galanti, B, Nardiello, S, Felaco, Mf, Pasquale, G, Marrone, Aldo, Aprea, L, Pizzella, T, Digilio, L, Cesaro, G, Sardaro, C, Santarpia, L, Adinolfi, Luigi Elio, Andreana, A, Russo, M, Filippini, Pietro, Zampino, Rosa, Piccinino, F, Ruggiero, G, and Giusti, G.

Published
1994

29. L'endocardite da Enterococco: nostra esperienza nel periodo 1988-93

Author

UTILI, Riccardo, ADINOLFI, Luigi Elio, Rosario P, Tripodi MF, Attanasio V, Andreana A, Cesaro G, Santarpia L, Ruggiero G., ZAMPINO, Rosa, Utili, Riccardo, Adinolfi, Luigi Elio, Rosario, P, Tripodi, Mf, Attanasio, V, Andreana, A, Cesaro, G, Santarpia, L, Zampino, Rosa, and Ruggiero, G.

Published
1993

30. Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B

Author

MARRONE, Aldo, UTILI, Riccardo, ADINOLFI, Luigi Elio, ZAMPINO, Rosa, Di Nuzzo S, Cesaro G, Piccinino R, Ragone E, Tripodi MF, Nardiello S, Pizzella T, Santarpia L, Ruggiero G., Marrone, Aldo, Utili, Riccardo, Adinolfi, Luigi Elio, Zampino, Rosa, Di Nuzzo, S, Cesaro, G, Piccinino, R, Ragone, E, Tripodi, Mf, Nardiello, S, Pizzella, T, Santarpia, L, and Ruggiero, G.

Published
1993

31. EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV

Author

UTILI, Riccardo, ZAMPINO, Rosa, Cesaro G, Andreana A, Rosario P, ADINOLFI, Luigi Elio, Attanasio V, Piccinino R, Casella D, Santarpia L, Tripodi MF, Ruggiero G., MARRONE, Aldo, Utili, Riccardo, Marrone, Aldo, Zampino, Rosa, Cesaro, G, Andreana, A, Rosario, P, Adinolfi, Luigi Elio, Attanasio, V, Piccinino, R, Casella, D, Santarpia, L, Tripodi, Mf, and Ruggiero, G.

Published
1992

32. Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali

Author

UTILI, Riccardo, MARRONE, Aldo, ROSARIO P, ANDREANA A, CESARO G, SANTARPIA L, CASELLA D, ADINOLFI, Luigi Elio, PICCININO R, TRIPODI MF, ATTANASIO V, RUGGIERO G., ZAMPINO, Rosa, Utili, Riccardo, Marrone, Aldo, Zampino, Rosa, Rosario, P, A., Andreana, Cesaro, G, Santarpia, L, Casella, D, Adinolfi, Luigi Elio, Piccinino, R, Tripodi, Mf, Attanasio, V, Ruggiero, G., and Andreana, A

Published
1992

34. Effect of prednisone priming followed by alpha-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trial

Author

UTILI, Riccardo, SAGNELLI E, GIUSTI G, RUGGIERO G, PICCININO F, GALANTI B, ADINOLFI, Luigi Elio, APREA L, CESARO G, DIGILIO L, FELACO FM, FILIPPINI, Pietro, GAETA, Giovanni Battista, NARDIELLO S, PASQUALE G, PIZZELLA T, RUSSO M, SANTARPIA L, SARDARO C. AND DAMORA T. ARCH VIROL SUPPL, MARRONE, Aldo, Utili, Riccardo, Sagnelli, E, Giusti, G, Ruggiero, G, Piccinino, F, Galanti, B, Adinolfi, Luigi Elio, Aprea, L, Cesaro, G, Digilio, L, Felaco, Fm, Filippini, Pietro, Gaeta, Giovanni Battista, Marrone, Aldo, Nardiello, S, Pasquale, G, Pizzella, T, Russo, M, Santarpia, L, and SARDARO C. AND DAMORA T., ARCH VIROL SUPPL

Published
1992

35. Effect of prednisone priming followed by alfa-interferon (IFN) in treatment of children with chronic hepatitis B: an interim analysis of a placebo-controlled trial

Author

UTILI, Riccardo, Sagnelli E, Giusti G, Ruggiero G, Piccinino P, Galanti B, ADINOLFI, Luigi Elio, Aprea L, Cesaro G, Digilio L, Felaco F, Filippini P, GAETA, Giovanni Battista, Nardiello S, Pasquale G, Pizzella T, Russ M, Santarpia L, Sardaro C, D'Amora T., MARRONE, Aldo, Utili, Riccardo, Sagnelli, E, Giusti, G, Ruggiero, G, Piccinino, P, Galanti, B, Adinolfi, Luigi Elio, Aprea, L, Cesaro, G, Digilio, L, Felaco, F, Filippini, P, Gaeta, Giovanni Battista, Marrone, Aldo, Nardiello, S, Pasquale, G, Pizzella, T, Russ, M, Santarpia, L, Sardaro, C, and D'Amora, T.

Published
1990

45. Moving on: How to switch young people with chronic intestinal failure from pediatric to adult care. a position statement by italian society of gastroenterology and hepatology and nutrition (SIGENP) and italian society of artificial nutrition and metabolism (SINPE)

Author

Paolo Gandullia, Antonella Lezo, Antonella Diamanti, Laura Lacitignola, Loris Pironi, Antonella De Francesco, Lidia Santarpia, Maria Immacolata Spagnuolo, Lorenzo Norsa, Teresa Capriati, Francesco Walter Guglielmi, Diamanti, A., Capriati, T., Lezo, A., Spagnuolo, M. I., Gandullia, P., Norsa, L., Lacitignola, L., Santarpia, L., Guglielmi, F. W., De Francesco, A., Pironi, L., Diamanti A., Capriati T., Lezo A., Spagnuolo M.I., Gandullia P., Norsa L., Lacitignola L., Santarpia L., Guglielmi F.W., De Francesco A., and Pironi L.

Subjects
Position statement, Adult, Male, medicine.medical_specialty, Transition to Adult Care, Consensus, Artificial nutrition, Adult care, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Child, Pediatric gastroenterology, Hepatology, business.industry, Self-Management, Gastroenterology, Intestinal failure, Parenteral nutrition, Chronic intestinal failure, Intestinal Diseases, 030220 oncology & carcinogenesis, Family medicine, Chronic Disease, Practice Guidelines as Topic, Transition of care, Continuity of care, 030211 gastroenterology & hepatology, Female, Sexual Health, business, Parenteral Nutrition, Home, Multidisciplinary rehabilitation
Abstract

In 2019 the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) and the Italian Society of Artificial Nutrition and Metabolism (SINPE) created a joint panel of experts with the aim of preparing an official statement on transition in Chronic Intestinal Failure (CIF). The transition from pediatric to adult care has a key role in managing all chronic diseases and in optimizing the compliance to care. Thus SIGENP and SINPE, in light of the growing number of patients with IF who need long-term Parenteral Nutrition (PN) and multidisciplinary rehabilitation programs throughout adulthood, shared a common protocol to provide an accurate and timely process of transition from pediatric to adult centers for CIF. The main objectives of the transition process for CIF can be summarized as the so-called "acronym of the 5 M": 1)Motivate independent choices which are characteristics of the adult world; 2)Move towards adult goals (e.g. self-management of his pathology and sexual issues); 3)Maintain the habitual mode of care; 4) Minimize the difficulties involved in the transition process and 5)Modulate the length of the transition so as to fully share with the adult's team the children's peculiarities.

Published
2020

46. Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B

Author

A, Marrone, R, Zampino, G, Portella, M, Grimaldi, E, Durante-Mangoni, E D, Mangoni, L, Santarpia, G, Ruggiero, R, Utili, Marrone, A., Zampino, R., Portella, Giuseppe, Grimaldi, M., Durante Mangoni, E., Santarpia, L., Ruggiero, G., Utili, R., Marrone, Aldo, Zampino, Rosa, Portella, G, Grimaldi, M, DURANTE MANGONI, Emanuele, Santarpia, L, and Utili, Riccardo

Subjects
Male, medicine.disease_cause, Severity of Illness Index, Liver Function Tests, Interferon, Prospective Studies, Child, education.field_of_study, Age Factors, virus diseases, Lamivudine, Recombinant Proteins, Infectious Diseases, Treatment Outcome, HBeAg, Drug Therapy, Combination, Female, Viral load, medicine.drug, Adult, Hepatitis B virus, Adolescent, medicine.drug_class, Population, Interferon alpha-2, Immunostimulant, Risk Assessment, Drug Administration Schedule, Sampling Studies, Statistics, Nonparametric, chronic B hepatitis, Hepatitis B, Chronic, Virology, medicine, Humans, Seroconversion, education, Probability, Hepatology, Dose-Response Relationship, Drug, business.industry, amivudine, HBeAg positive, Interferon-alpha, interferon, digestive system diseases, business, Follow-Up Studies
Abstract

Summary. Alpha-interferon (IFN) or lamivudine monotherapy are ineffective in treating chronic HBeAg positive patients with high viral load and low alanine aminotransferase (ALT) levels. We investigated whether priming lamivudine treatment might enhance the antiviral and immunostimulant action of lamivudine/IFN combination in young tolerant patients. Eleven chronic HBeAg positive patients received: 100 mg/day lamivudine for 3 months followed by IFN 5 MU/m2/tiw with lamivudine 100 mg/day for 6 months and then lamivudine alone 100 mg/day for 9 months. Quantitative hepatitis B virus (HBV)-DNA was evaluated during treatment and core-promoter, precore and polymerase HBV mutants were detected by direct sequencing at the end of therapy. Serum HBV-DNA levels dropped during lamivudine monotherapy and in combination with IFN. After IFN withdrawal, viraemia transiently increased to high levels in five of 11 (45%) patients who showed rt M204V/I lamivudine mutant resistant. Two patients cleared HBeAg without anti-HBe seroconversion. One patient presented core-promoter (A1762T/G1764A) and precore stop codon mutations. Hence, three-phase sequential combined lamivudine/IFN treatment reduced HBV-DNA serum level, but did not lead to HBeAg and HBV-DNA clearance in these highly viraemic, normal ALT patients. Lamivudine/IFN combination did not prevent the emergence of YMDD lamivudine resistance. New schedules of antiviral treatments must be evaluated in this population at risk of disease progression.

Published
2005

47. New Predictive Equations for Estimating Resting Energy Expenditure in Adults With Crohn's Disease

Author

Nicola Imperatore, Luca Scalfi, Maria Carmen Pagano, Maurizio Marra, D. Morlino, Olivia Di Vincenzo, Iolanda Cioffi, Fabrizio Pasanisi, Lidia Santarpia, Lucia Alfonsi, Fabiana Castiglione, Marra, M, Cioffi, I, Morlino, D, Vincenzo, Od, Pagano, Mc, Imperatore, N, Alfonsi, L, Santarpia, L, Castiglione, F, Scalfi, L, and Pasanisi, F.

Subjects
Adult, Male, Adolescent, Population level, 030309 nutrition & dietetics, Population, dietary advice, Medicine (miscellaneous), Body Mass Index, predictive equations, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, GTP-Binding Proteins, Predictive Value of Tests, Weight loss, Statistics, energy expenditure, medicine, Humans, Resting energy expenditure, education, Aged, Mathematics, 0303 health sciences, Crohn's disease, education.field_of_study, Nutrition and Dietetics, Original Communication, accuracy, Reproducibility of Results, Calorimetry, Indirect, Regression analysis, Middle Aged, Anthropometry, medicine.disease, Individual level, Original Communications, Female, 030211 gastroenterology & hepatology, Basal Metabolism, medicine.symptom, Energy Metabolism
Abstract

Background Increased resting energy expenditure (REE) has been hypothesized to be a potential cause of weight loss in individuals with Crohn's disease (CD). This study aimed to develop and validate new predictive equations for estimating REE in adults with CD. Methods Adults, ages 18–65 years, with CD were recruited. Anthropometry, indirect calorimetry, and bioimpedance analysis were performed in all patients. Disease activity was assessed by Crohn's Disease Activity Index. The new predictive equations were generated using different regression models. Prediction accuracy of the new equations was assessed and compared with the most commonly used equations. Results A total of 270 CD patients (159 males, 111 females) were included and randomly assigned to the calibration (n = 180) and validation groups (n = 90). REE was directly correlated with weight and bioimpedance index, whereas the relation with both age and disease activity was inverse. The new equations were suitable for estimating REE at population level (bias: −0.2 and −0.3, respectively). Individual accuracy was good in both models (≥80%, respectively), especially in females; and similar results were shown by some of the selected equations. But, when accuracy was set within ±5%, the new equations gave the highest prediction. Conclusion The new, disease‐specific, equations for predicting REE in individuals with CD give a good prediction accuracy as far as those proposed in the literature for the general population. However, the new ones performed better at the individual level. Further studies are needed to verify the reliability and usefulness of these new equations.

Published
2020

48. Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure

Author

Nuria Virgili, Konrad Matysiak, Cristina Cuerda, Henrik Højgaard Rasmussen, Florian Poullenot, Ronan Thibault, Umberto Aimasso, Amelia Jukes, Andre Dong Won Lee, Brooke Chapman, Geert J. A. Wanten, Simona Di Caro, Maryana Doitchinova-Simeonova, Alastair Forbes, Corrado Spaggiari, Ezra Steiger, Elena Nardi, Cécile Chambrier, Simon Lal, Paolo Orlandoni, Peter Sahin, Marina Taus, Mireille J. Serlie, Kinga Szczepanek, A. Crivelli, Nicola Wyer, Przemysław Matras, Lynn Jones, Carmen Garde, Gabriel Olveira, Marek Kunecki, José P. Suárez-Llanos, Francisca Joly, Ana Zugasti Murillo, Joanne Daniels, Loris Pironi, Zeljko Krznaric, Emma Osland, Sheldon C. Cooper, Stéphane M. Schneider, Sarah Jane Hughes, Lars Ellegård, Miriam Theilla, Luisa Masconale, Anna Zmarzly, Aurora E. Serralde-Zúñiga, André Van Gossum, Anna Simona Sasdelli, Lidia Santarpia, Nada Rotovnik Kozjek, Francesco William Guglielmi, Margie O'Callaghan, Charlene Compher, Estrella Petrina Jáuregui, Pironi, L., Steiger, E., Joly, F., Wanten, G. J. A., Chambrier, C., Aimasso, U., Sasdelli, A. S., Szczepanek, K., Jukes, A., Theilla, M., Kunecki, M., Daniels, J., Serlie, M. J., Cooper, S. C., Poullenot, F., Rasmussen, H. Ho., Compher, C. W., Crivelli, A., Hughes, S. -J., Santarpia, L., Guglielmi, F. W., Rotovnik Kozjek, N., Ellegard, L., Schneider, S. M., Matras, P., Forbes, A., Wyer, N., Zmarzly, A., Taus, M., O'Callaghan, M., Osland, E., Thibault, R., Cuerda, C., Jones, L., Chapman, B., Sahin, P., Virgili, N. M., Lee, A. D. W., Orlandoni, P., Matysiak, K., Di Caro, S., Doitchinova-Simeonova, M., Masconale, L., Spaggiari, C., Garde, C., Serralde-Zuniga, A. E., Olveira, G., Krznaric, Z., Petrina Jauregui, E., Zugasti Murillo, A., Suarez-Llanos, J. P., Nardi, E., Van Gossum, A., Lal, S., Pironi, Lori, Steiger, Ezra, Joly, Francisca, Wanten, Geert J A, Chambrier, Cecile, Aimasso, Umberto, Sasdelli, Anna Simona, Szczepanek, Kinga, Jukes, Amelia, Theilla, Miriam, Kunecki, Marek, Daniels, Joanne, Serlie, Mireille J, Cooper, Sheldon C, Poullenot, Florian, Rasmussen, Henrik Højgaard, Compher, Charlene W, Crivelli, Adriana, Hughes, Sarah-Jane, Santarpia, Lidia, Guglielmi, Francesco William, Rotovnik Kozjek, Nada, Ellegard, Lar, Schneider, Stéphane M, Matras, Przemysław, Forbes, Alastair, Wyer, Nicola, Zmarzly, Anna, Taus, Marina, O'Callaghan, Margie, Osland, Emma, Thibault, Ronan, Cuerda, Cristina, Jones, Lynn, Chapman, Brooke, Sahin, Peter, Virgili, Núria M, Lee, Andre Dong Won, Orlandoni, Paolo, Matysiak, Konrad, Di Caro, Simona, Doitchinova-Simeonova, Maryana, Masconale, Luisa, Spaggiari, Corrado, Garde, Carmen, Serralde-Zúñiga, Aurora E, Olveira, Gabriel, Krznaric, Zeljko, Petrina Jáuregui, Estrella, Zugasti Murillo, Ana, Suárez-Llanos, José P, Nardi, Elena, Van Gossum, André, Lal, Simon, University of Bologna, Cleveland Clinic, Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Radboud university [Nijmegen], Hospices Civils de Lyon (HCL), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Aalborg University [Denmark] (AAU), Sahlgrenska Academy at University of Gothenburg [Göteborg], Centre Hospitalier Universitaire de Nice (CHU Nice), Medical University of Lublin, University of East Anglia [Norwich] (UEA), University Hospital Coventry, CHU Pontchaillou [Rennes], Nutrition, Métabolismes et Cancer (NuMeCan), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Hospital General Universitario 'Gregorio Marañón' [Madrid], Austin Health, Universidade de São Paulo (USP), Poznan University of Life Sciences (Uniwersytet Przyrodniczy w Poznaniu) (PULS), University College London Hospitals (UCLH), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán - National Institute of Medical Science and Nutrition Salvador Zubiran [Mexico], University of Manchester [Manchester], European Society for Clinical Nutrition and Metabolism (ESPEN)., Endocrinology, AGEM - Endocrinology, metabolism and nutrition, University of Bologna/Università di Bologna, Radboud University [Nijmegen], Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Universidade de São Paulo = University of São Paulo (USP)

Subjects
Male, 0301 basic medicine, [SDV]Life Sciences [q-bio], Severity of Illness Index, Liver disease, 0302 clinical medicine, Drug Dosage Calculations, motility disorder, 2. Zero hunger, Gastroenterology, Short bowel syndrome, 3. Good health, Chronic intestinal failure, Intestines, Pharmaceutical Solutions, Venous thrombosis, Intestinal obstruction, motility disorders, Administration, Intravenous, Female, 030211 gastroenterology & hepatology, Parenteral Nutrition, Home, Adult, Fat Emulsions, Intravenous, medicine.medical_specialty, parenteral nutrition, macromolecular substances, Clinical nutrition, short bowel syndrome, 03 medical and health sciences, Cholestasis, intestinal failure, Internal medicine, medicine, Humans, 030109 nutrition & dietetics, business.industry, liver failure, medicine.disease, Intestinal Diseases, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Parenteral nutrition, Alimentació parenteral, Intestinal Absorption, Catheter-Related Infections, Parenteral feeding, Chronic Disease, Obstrucció intestinal, Fluid Therapy, business, Body mass index
Abstract

Background and aimNo marker to categorise the severity of chronic intestinal failure (CIF) has been developed. A 1-year international survey was carried out to investigate whether the European Society for Clinical Nutrition and Metabolism clinical classification of CIF, based on the type and volume of the intravenous supplementation (IVS), could be an indicator of CIF severity.MethodsAt baseline, participating home parenteral nutrition (HPN) centres enrolled all adults with ongoing CIF due to non-malignant disease; demographic data, body mass index, CIF mechanism, underlying disease, HPN duration and IVS category were recorded for each patient. The type of IVS was classified as fluid and electrolyte alone (FE) or parenteral nutrition admixture (PN). The mean daily IVS volume, calculated on a weekly basis, was categorised as 3 L/day. The severity of CIF was determined by patient outcome (still on HPN, weaned from HPN, deceased) and the occurrence of major HPN/CIF-related complications: intestinal failure-associated liver disease (IFALD), catheter-related venous thrombosis and catheter-related bloodstream infection (CRBSI).ResultsFifty-one HPN centres included 2194 patients. The analysis showed that both IVS type and volume were independently associated with the odds of weaning from HPN (significantly higher for PN 1 L/day), patients’ death (lower for FE, p=0.079), presence of IFALD cholestasis/liver failure and occurrence of CRBSI (significantly higher for PN 2–3 and PN >3 L/day).ConclusionsThe type and volume of IVS required by patients with CIF could be indicators to categorise the severity of CIF in both clinical practice and research protocols.

Published
2020

49. Nutritional Screening and Anthropometry in Patients Admitted From the Emergency Department

Author

Enza Speranza, Lidia Santarpia, Maurizio Marra, Olivia Di Vincenzo, Marianna Naccarato, Carmela De Caprio, Delia Morlino, Gaetano D'Onofrio, Franco Contaldo, Fabrizio Pasanisi, Speranza, E., Santarpia, L., Marra, M., Di Vincenzo, O., Naccarato, M., De Caprio, C., Morlino, D., D'Onofrio, G., Contaldo, F., and Pasanisi, F.

Subjects
Nutrition and Dietetics, Nutritional Risk Screening (NRS 2002), Hospital malnutrition, Nutrition. Foods and food supply, Subjective Global Assessment (SGA), Endocrinology, Diabetes and Metabolism, GLIM criteria, anthropometry measurements, TX341-641, malnutrition risk, anthropometry measurement, Food Science
Abstract

BackgroundDue to the high prevalence of malnutrition among hospitalized patients, screening and assessment of nutritional status should be routinely performed upon hospital admission. The main objective of this observational study was to evaluate the prevalence of and the risk for malnutrition, as identified by using three nutritional screening tests, and to observe whether some anthropometric and functional parameters used for nutritional evaluation were related to these test scores.MethodsThis single-center observational study included 207 patients admitted from the emergency department for hospitalization in either the internal medicine or surgery units of our institution from September 2017 to December 2018. The prevalence of malnutrition among this patient sample was evaluated by using the Nutritional Risk Screening (NRS-2002), the Subjective Global Assessment (SGA) and the Global Leadership Initiative on Malnutrition (GLIM) criteria. Body mass index (BMI), bioimpedance analysis (BIA), handgrip strength (HGS) and calf circumference (CC) assessments were also performed.ResultsAccording to the NRS-2002, 93% of the patients were at no risk or at low nutritional risk (NRS score < 3), and 7% were at a high nutritional risk (NRS score ≥ 3). On the other hand, according to the SGA, 46.3% of the patients were well-nourished (SGA-a), 49.8% were moderately malnourished (SGA-b), and 3.9% were severely malnourished (SGA-c). Finally, according to the GLIM criteria, 18% patients were malnourished. Body weight, body mass index (BMI), phase angle (PhA), CC and HGS were significantly lower in the patients with NRS scores ≥ 3, SGA-c and in patients with stage 1 and stage 2 malnutrition, according to the GLIM criteria.ConclusionThe NRS-2002, the SGA and the GLIM criteria appear to be valuable tools for the screening and assessment of nutritional status. In particular, the lowest NRS-2002, SGA and GLIM scores were associated with the lowest PhA and CC. Nevertheless, a weekly re-evaluation of patients with better screening and assessment scores is recommended to facilitate early detection of changes in nutritional status.

Published
2022

50. Characteristics of adult patients with chronic intestinal failure due to short bowel syndrome:An international multicenter survey

Author

Loris Pironi, Ezra Steiger, Francisca Joly, Palle B. Jeppesen, Geert Wanten, Anna S. Sasdelli, Cecile Chambrier, Umberto Aimasso, Manpreet S. Mundi, Kinga Szczepanek, Amelia Jukes, Miriam Theilla, Marek Kunecki, Joanne Daniels, Mireille Serlie, Florian Poullenot, Sheldon C. Cooper, Henrik H. Rasmussen, Charlene Compher, David Seguy, Adriana Crivelli, Lidia Santarpia, Francesco W. Guglielmi, Nada Rotovnik Kozjek, Stéphane M. Schneider, Lars Ellegard, Ronan Thibault, Przemysław Matras, Konrad Matysiak, Andrè Van Gossum, Alastair Forbes, Nicola Wyer, Marina Taus, Nuria M. Virgili, Margie O'Callaghan, Brooke Chapman, Emma Osland, Cristina Cuerda, Gábor Udvarhelyi, Lynn Jones, Andre D. Won Lee, Luisa Masconale, Paolo Orlandoni, Corrado Spaggiari, Marta Bueno Díez, Maryana Doitchinova-Simeonova, Aurora E. Serralde-Zúñiga, Gabriel Olveira, Zeljko Krznaric, Laszlo Czako, Gintautas Kekstas, Alejandro Sanz-Paris, Mª Estrella Petrina Jáuregui, Ana Zugasti Murillo, Eszter Schafer, Jann Arends, José P. Suárez-Llanos, Nader N. Youssef, Giorgia Brillanti, Elena Nardi, Simon Lal, Adriana N. Crivelli, Hector Solar Muñiz, Brooke R. Chapman, Ruth Hodgson, Siobhan Wallin, Kay Lasenby, Andre Van Gossum, Andre Dong Won Lee, Henrik Højgaard Rasmussen, Chrisoffer Brandt, Vanessa Boehm, Julie Bataille, Lore Billiauws, Tomas Molnar, Mihaly Zsilak-Urban, Ferenc Izbéki, Peter Sahin, Anna Simona Sasdelli, Merlo F. Dario, Valentino Bertasi, Nunzia Regano, Santarpia Lidia, Lucia Alfonsi, Debora Busni, Lyn Gillanders, Anna Zmarzly, Marta Bueno, Carmen Garde, Ma Estrella Petrina Jáuregui, Cora Jonker, Simona Di Caro, Niamh Keane, Pinal Patel, Sarah-Jane Nelson Hughes, Rachel Lloyd, Arun Abraham, Gerda Garside, Michael Taylor, Jian Wu, Trevor Smith, Charlotte Pither, Michael Stroud, Reena Parmar, Nicola Burch, Sarah Zeraschi, Manpreet Mundi, Denise Jezerski, Pironi L., Steiger E., Joly F., Jeppesen P.B., Wanten G., Sasdelli A.S., Chambrier C., Aimasso U., Mundi M.M., Szczepanek K., Jukes A., Theilla M., Kunecki M., Daniels J., Serlie M., Poullenot F., Cooper S.C., Rasmussen H.H., Compher C., Seguy D., Crivelli A., Santarpia L., Guglielmi F.W., Kozjek N.R., Schneider S.M., Ellegard L., Thibault R., Matras P., Matysiak K., Van Gossum A., Forbes A., Wyer N., Taus M., Virgili N.M., O'Callaghan M., Chapman B., Osland E., Cuerda C., Udvarhelyi G., Jones L., Won Lee A.D., Masconale L., Orlandoni P., Spaggiari C., Diez M.B., Doitchinova-Simeonova M., Serralde-Zuniga A.E., Olveira G., Krznaric Z., Czako L., Kekstas G., Sanz-Paris A., Jauregui M.E.P., Murillo A.Z., Schafer E., Arends J., Suarez-Llanos J.P., Youssef N.N., Brillanti G., Nardi E., Lal S., Crivelli A.N., Muniz H.S., Chapman B.R., Hodgson R., Wallin S., Lasenby K., Brandt C., Boehm V., Bataille J., Billiauws L., Molnar T., Zsilak-Urban M., Izbeki F., Sahin P., Dario M.F., Bertasi V., Regano N., Lidia S., Alfonsi L., Busni D., Gillanders L., Zmarzly A., Bueno M., Garde C., Jonker C., Di Caro S., Keane N., Patel P., Nelson Hughes S.-J., Lloyd R., Abraham A., Garside G., Taylor M., Wu J., Smith T., Pither C., Stroud M., Parmar R., Burch N., Zeraschi S., Mundi M., Jezerski D., Endocrinology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, University of Bologna, Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Cleveland Clinic, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Radboud University Medical Center [Nijmegen], Hospices Civils de Lyon (HCL), Città della Salute e della Scienza University-Hospital, Mayo Clinic and Mayo College of Medicine, Rochester, Stanley Dudrick's Memorial Hospital, Partenaires INRAE, University Hospital of Wales, Tel Aviv University [Tel Aviv], University of Lódź, Nottingham University Hospitals NHS Trust [UK], VU University Medical Center [Amsterdam], CHU Bordeaux [Bordeaux], University Hospitals Birmingham NHS Foundation Trust, Aalborg University Hospital, Hospital of the University of Pennsylvania (HUP), Perelman School of Medicine, University of Pennsylvania [Philadelphia]-University of Pennsylvania [Philadelphia], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hospital Universitario Fundacion Favaloro, University of Naples Federico II, Monsignor di Miccoli Hospital, Institute of Oncology - Ljubljana, Institute of Oncology Ljubljana, Centre Hospitalier Universitaire de Nice (CHU Nice), University of Gothenburg (GU), The project of the ESPEN database for Chronic Intestinal Failure was promoted by the ESPEN Executive Committee in 2013, was approved by the ESPEN Council and was supported by an ESPEN grant., University of Bologna/Università di Bologna, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University Hospital of Wales (UHW), Tel Aviv University (TAU), Nottingham University Hospitals NHS Trust (NUH), University of Pennsylvania-University of Pennsylvania, University of Naples Federico II = Università degli studi di Napoli Federico II, and Institute of Oncology [Ljubljana]

Subjects
Parenteral Nutrition, Epidemiology, [SDV]Life Sciences [q-bio], Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, MESH: Intestinal Diseases, Malalties intestinals, 0302 clinical medicine, Indicadors de salut, Medicine, 030212 general & internal medicine, Intestines--Diseases, Nutrition and Dietetics, Intestinal Disease, Short bowel syndrome, Intestinal failure, Health status indicators, 3. Good health, Chronic intestinal failure, Intestine, Intestines, medicine.anatomical_structure, Cohort, 030211 gastroenterology & hepatology, Female, MESH: Intestines, Human, Adult, Short Bowel Syndrome, medicine.medical_specialty, Anastomosis, 03 medical and health sciences, Ileocecal valve, MESH: Cross-Sectional Studies, epidemiology, home parenteral nutrition, intestinal failure, intravenous supplementation, short bowel syndrome, Internal medicine, MESH: Short Bowel Syndrome, Humans, Cross-Sectional Studie, Home parenteral nutrition, MESH: Humans, business.industry, MESH: Adult, medicine.disease, Intravenous supplementation, Intestinal Diseases, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Parenteral nutrition, Cross-Sectional Studies, Jejunostomy, business, MESH: Female, MESH: Parenteral Nutrition
Abstract

Contains fulltext : 244566.pdf (Publisher’s version ) (Closed access) BACKGROUND AND AIMS: The case-mix of patients with intestinal failure due to short bowel syndrome (SBS-IF) can differ among centres and may also be affected by the timeframe of data collection. Therefore, the ESPEN international multicenter cross-sectional survey was analyzed to compare the characteristics of SBS-IF cohorts collected within the same timeframe in different countries. METHODS: The study included 1880 adult SBS-IF patients collected in 2015 by 65 centres from 22 countries. The demographic, nutritional, SBS type (end jejunostomy, SBS-J; jejuno-colic anastomosis, SBS-JC; jejunoileal anastomosis with an intact colon and ileocecal valve, SBS-JIC), underlying disease and intravenous supplementation (IVS) characteristics were analyzed. IVS was classified as fluid and electrolyte alone (FE) or parenteral nutrition admixture (PN). The mean daily IVS volume, calculated on a weekly basis, was categorized as 3 L/day. RESULTS: In the entire group: 60.7% were females and SBS-J comprised 60% of cases, while mesenteric ischaemia (MI) and Crohn' disease (CD) were the main underlying diseases. IVS dependency was longer than 3 years in around 50% of cases; IVS was infused ≥5 days/week in 75% and FE in 10% of cases. Within the SBS-IF cohort: CD was twice and thrice more frequent in SBS-J than SBS-JC and SBS-JIC, respectively, while MI was more frequent in SBS-JC and SBS-JIC. Within countries: SBS-J represented 75% or more of patients in UK and Denmark and 50-60% in the other countries, except Poland where SBS-JC prevailed. CD was the main underlying disease in UK, USA, Denmark and The Netherlands, while MI prevailed in France, Italy and Poland. CONCLUSIONS: SBS-IF type is primarily determined by the underlying disease, with significant variation between countries. These novel data will be useful for planning and managing both clinical activity and research studies on SBS.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results